Association of the TNFRSF1B-rs1061622 variant with nonresponse to infliximab in ulcerative colitis

Association of the TNFRSF1B-rs1061622 variant with nonresponse to infliximab in ulcerative colitis

Abstract For severe forms of ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), biological therapies, including tumor necrosis factor inhibitors (anti-TNF), are often used. However, these drugs have a high variability in treatment response. Multiple factors, such as genetic variant...

Full description

Saved in:
Bibliographic Details
Main Authors: Laurence Tessier, Ann-Lorie Gagnon, Sophie St-Amour, Mathilde Côté, Catherine Allard, Mathieu Durand, Danny Bergeron, Alexandre Lavoie, Alban Michaud-Herbst, Karine Tremblay
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-025-02463-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-02463-4

Similar Items